BioNTech SE Company Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.

The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors.

It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor.

BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

BioNTech SE

Country	Germany
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	6,772
CEO	Ugur Sahin

Contact Details

Address: An der Goldgrube 12 Mainz, 55131 Germany
Phone	49 6131 9084
Website	biontech.de

Stock Details

Ticker Symbol	22UA
Exchange	Deutsche Börse Xetra
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	US09075V1026
SIC Code	2836

Key Executives

Name	Position
Dr. Ugur Sahin M.D.	Co-Founder, Chief Executive Officer and Chair of the Management Board
Dr. Ozlem Tureci M.D.	Co-Founder, Chief Medical Officer and Member of Management Board